Costs and Clinical Consequences of Compliance with COPD GOLD Recommendations or National Guidelines Compared with Current Clinical Practice in Belgium, Germany, Sweden, and the United States

References

• Humenberger M, Horner A, Labek A, et al. Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD). BMC Pulm Med. 2018;18(1):163. doi:10.1186/s12890-018-0724-3
   PubMed Web of Science ®Google Scholar
• Soriano JB, Abajobir AA, Abate KH; GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691–706.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2022. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed November 1, 2021.
   Google Scholar
• Vogelmeier C, Buhl R, Burghuber O, et al. Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD) herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. und der Deutschen Atemwegsliga e. V., unter Beteiligung der Österreichischen Gesellschaft für Pneumologie. [Guideline for the diagnosis and treatment of COPD patients: issued by the German Respiratory Society and the German Respiratory League in co-operation with the Austrian Society of Pneumology]. Pneumologie. 2018;72(4):253–308. German. doi:10.1055/s-0043-125031
   PubMed Web of Science ®Google Scholar
• Bloom CI, Elkin SL, Quint JK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287. doi:10.2147/COPD.S190086
   PubMed Web of Science ®Google Scholar
• Adir Y, Horner A, de Vries GJ, et al. Treatment patterns in stable COPD patients – results from a large observational European study (SPACE). Eur Respir J. 2019;54(suppl 63):PA2509. doi:10.1183/13993003.congress-2019.PA2509
   Web of Science ®Google Scholar
• Chalmers JD, Poole C, Webster S, Tebboth A, Dickinson S, Gayle A. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the clinical practice research data. Respir Res. 2018;19(1):63. doi:10.1186/s12931-018-0767-2
   PubMed Web of Science ®Google Scholar
• Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH. Medical treatment of COPD. Dtsch Arztebl Int. 2018;155(37):599–605. doi:10.3238/arztebl.2018.0599
   PubMed Web of Science ®Google Scholar
• Palmiotti GA, Lacedonia D, Liotino V, et al. Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy. Int J Chron Obstruct Pulmon Dis. 2018;13:2455–2462. doi:10.2147/COPD.S157779
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Navarrete BA, Soriano JB, et al. Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. Int J Chron Obstruct Pulmon Dis. 2018;13:2279–2288. doi:10.2147/COPD.S160842
   PubMed Web of Science ®Google Scholar
• Sundh J, Åberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1):1409060. doi:10.1080/20018525.2017.1409060
   PubMed Web of Science ®Google Scholar
• Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83. doi:10.2147/COPD.S122013
   PubMed Web of Science ®Google Scholar
• Dhalwani N, Cabrera C, Booth A, Petrella R, Lambrelli D. Characteristics and treatment patterns of newly diagnosed COPD patients in Canada. Eur Respir J. 2019;54(Suppl 63):PA3385. doi:10.1183/13993003.congress-2019.PA3385
   Web of Science ®Google Scholar
• Reddel HK, Valenti L, Easton KL, Gordon J, Bayram C, Miller GC. Assessment and management of asthma and chronic obstructive pulmonary disease in Australian general practice. Aus Fam Physician. 2017;46(6):413–419.
   PubMedGoogle Scholar
• Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172. doi:10.18553/jmcp.2018.24.11.1165
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10(1):2207–2217. doi:10.2147/COPD.S91694
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111:47–53. doi:10.1016/j.rmed.2015.12.004
   PubMed Web of Science ®Google Scholar
• Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. EClinicalMedicine. 2019;14:32–41. doi:10.1016/j.eclinm.2019.07.003
   PubMedGoogle Scholar
• Zheng Y, Zhu J, Liu Y, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363:k4388. doi:10.1136/bmj.k4388
   PubMed Web of Science ®Google Scholar
• Izquierdo JL, Cosio BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulm Dis. 2018;13:3539–3547. doi:10.2147/COPD.S175047
   PubMed Web of Science ®Google Scholar
• Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease. J Comp Eff Res. 2019;8(15):1299–1316. doi:10.2217/cer-2019-0101
   PubMed Web of Science ®Google Scholar
• de Cock J. Het rationeel gebruik van geneesmiddelen in de onderhoudsbehandeling van COPD en astma bij de volwassene. [The rational use of drugs in the maintenance treatment of COPD and asthma in adults]. Dutch; 2017. Available from: https://www.riziv.fgov.be/SiteCollectionDocuments/consensus_korte_tekst_20170511.pdf. Accessed August 22, 2022.
   Google Scholar
• Worth H, Buhl R, Criée CP, Kardos P, Mailänder C, Vogelmeier C. The “real-life” COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64–71. doi:10.1016/j.rmed.2015.12.010
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Bakke P, Ekroos H, et al. Investigating the drivers for COPD treatment decisions. Eur Respir J. 2021;58(suppl 65):PA2413.
   Google Scholar
• Swedish National Airways Register. Luftvägsregistret. [Swedish National Airways Register]. Swedish; 2020. Available from: https://lvr.registercentrum.se/nyheter?year=2020. Accessed June 30, 2020.
   Google Scholar
• Palli SR, Zhou S, Shaikh A, Willey VJ. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy. J Manag Care Spec Pharm. 2021;27(5):625–637. doi:10.18553/jmcp.2021.20390
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Kostikas K, Fang J, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178. doi:10.1186/s12931-019-1130-y
   PubMed Web of Science ®Google Scholar
• Ellingsen J, Janson C, Bröms K, et al. Longitudinal measurements of blood eosinophils in relation to COPD outcomes. Eur Respir J. 2018;52(suppl 62):PA2015. doi:10.1183/13993003.congress-2018.PA2015
   Web of Science ®Google Scholar
• Sulku J, Janson C, Melhus H, et al. A cross-sectional study assessing appropriateness of inhaled corticosteroid treatment in primary and secondary care patients with COPD in Sweden. Int J Chron Obstruct Pulmon Dis. 2019;14:2451–2460. doi:10.2147/COPD.S218747
   PubMed Web of Science ®Google Scholar
• Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs. Int J Chron Obstruct Pulmon Dis. 2018;13:3485–3492. doi:10.2147/COPD.S173664
   PubMed Web of Science ®Google Scholar
• Greulich T, Mager S, Lucke T, et al. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2018;13:2999–3002. doi:10.2147/COPD.S165909
   PubMed Web of Science ®Google Scholar
• Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;12(12):CD012620. doi:10.1002/14651858.CD012620.pub2
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586. doi:10.1183/13993003.01586-2018
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–229. doi:10.1001/archinternmed.2008.550
   PubMed Web of Science ®Google Scholar
• Grewe FA, Sievi NA, Bradicich M, et al. Compliance of pharmacotherapy with GOLD guidelines: a longitudinal study in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:627–635. doi:10.2147/COPD.S240444
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Barrecheguren M, Solntseva I, et al. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD. NPJ Prim Care Respir Med. 2021;31(1):16. doi:10.1038/s41533-021-00227-x
   PubMed Web of Science ®Google Scholar
• Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130–1139. doi:10.1164/RCCM.201804-0621CI
   PubMed Web of Science ®Google Scholar